Practice Point | Published:

Is rosiglitazone associated with increased risk for cardiovascular events?

Nature Clinical Practice Cardiovascular Medicine volume 4, pages 648649 (2007) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    (2002) PPARγ and vascular inflammation: adding another piece to the puzzle. Circ Res 91: 373–374

  2. 2.

    et al. for the DREAM Trial Investigators (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 368: 1096–1105

  3. 3.

    et al. for the ADOPT Study Group (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427–2443

  4. 4.

    et al. for the RECORD Study Group (2007) Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med 357: 28–38

  5. 5.

    and (2007) The rosiglitazone controversy: the Indian perspective. J Assoc Physicians India 55: 477–480

Download references

Acknowledgements

The synopsis was written by Alexandra King, Associate Editor, Nature Clinical Practice.

Author information

Affiliations

  1. M Hanefeld is Professor of Internal Medicine and Director of the Centre for Clinical Studies at the Technical University in Dresden, Germany.

    • Markolf Hanefeld

Authors

  1. Search for Markolf Hanefeld in:

Competing interests

M Hanefeld has acted as a Consultant for Bayer, GlaxoSmithKline, and Novo-Nordisk and has received Speakers' Bureau honoraria from Bayer, Novo-Nordisk, and Takeda.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/ncpcardio1030

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing